Therapeutic effects of a TBK1 kinase inhibitor in germinal center-driven, autoantibody-mediated inflammatory arthritis
Publication Year 2019-01, Volume 71, Issue #1, Page 50-62
Journal Title
Arthritis & Rheumatology
Publication Type
Journal Article
OBJECTIVE: The production of class-switched high-affinity autoantibodies derived from organised germinal centers (GC) is a hallmark of many autoimmune inflammatory diseases, including rheumatoid arthritis (RA). TANK-binding kinase 1 (TBK1) is a serine-threonine kinase involved in the maturation of GC T follicular B helper cells (TFH ) downstream of inducible T cell costimulator (ICOS) signalling. We therefore assessed the therapeutic potential of TBK1 inhibition using a small molecule inhibitor - known as WEHI-112 - in antibody dependent models of inflammatory arthritis. METHODS AND RESULTS: WEHI-112 - a tool compound, which is semi-selective for TBK1, but also has activity against IKKepsilon and JAK2 - abolished TBK1-dependent IRF3 activation and inhibited type I IFN responses in vitro. In vivo, treatment with WEHI-112 selectively abrogated clinical and histological features of established, antibody-dependent collagen-induced arthritis (CIA), but had minimal effects on an antibody-independent model of antigen-induced arthritis (AIA) or on K/BxN serum transfer-induced arthritis (STIA). In keeping with these findings, WEHI-112 reduced arthritogenic collagen type II (CII)-specific IgG1 and IgG2b antibody production. Furthermore, WEHI-112 altered the GC TFH phenotype and GC B cell function in CIA. CONCLUSION: In summary, we report that TBK1 inhibition using WEHI-112, albeit semi-selective for TBK1, abrogated antibody-dependent CIA, most likely explained by targeting TBK1-mediated mechanisms in the GC reaction as its major effect. This approach may have therapeutic potential in RA and in other GC-associated autoantibody-driven inflammatory diseases. This article is protected by copyright. All rights reserved.
WEHI Research Division(s)
Chemical Biology; Systems Biology And Personalised Medicine; Inflammation; Cancer And Haematology
PubMed ID
Publisher's Version
NHMRC Grants
NHMRC/1023407 NHMRC/1016647
Rights Notice
Refer to copyright notice on published article.

Creation Date: 2018-07-23 09:32:17
Last Modified: 2020-02-03 01:16:53
An error has occurred. This application may no longer respond until reloaded. Reload 🗙